Regeneron Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 30, 2026, 6:50 a.m. ETView on SEC.gov Our explainer
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedRegeneron Q3 2026 non-GAAP EPS of $20.07 beats $16.25 consensus as revenue rises 36% to $5.1 billion; Sanofi expansion adds $1.0 billion up-front for Q4
8-KOct. 6, 2026, 7:51 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Results of operations and financial condition · Other events
8-KSept. 30, 2026, 4:14 p.m. ETView on SEC.gov
Departure/appointment of directors or officers · Financial statements and exhibits
8-KJuly 30, 2026, 6:48 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits